Demographics of all patients by CTCL stage
| . | 280 mg zanolimumab . | 560 mg zanolimumab . | 980 mg zanolimumab . | |
|---|---|---|---|---|
| IB-IIA . | IIB-IVB . | IB-IIA . | IIB-IVB . | |
| No. of patients in each stage | 11 | 13 | 14 | 9 |
| CTCL subtype, no. MF/no. SS | 11/0 | 9/4 | 14/0 | 4/5 |
| Sex, no. male/no. female | 9/2 | 11/2 | 10/4 | 6/3 |
| Race, no. white/no. black | 11/0 | 13/0 | 14/0 | 8/1 |
| Median age, y (range) | 70 (53-81) | 57 (42-79) | 57.5 (36-80) | 58 (35-78) |
| Median duration of CTCL, y (range) | 2.2 (0.1-7.4) | 2.2 (0.5-13.7) | 5.3 (0.4-46.9) | 2.8 (0.8-7.5) |
| . | 280 mg zanolimumab . | 560 mg zanolimumab . | 980 mg zanolimumab . | |
|---|---|---|---|---|
| IB-IIA . | IIB-IVB . | IB-IIA . | IIB-IVB . | |
| No. of patients in each stage | 11 | 13 | 14 | 9 |
| CTCL subtype, no. MF/no. SS | 11/0 | 9/4 | 14/0 | 4/5 |
| Sex, no. male/no. female | 9/2 | 11/2 | 10/4 | 6/3 |
| Race, no. white/no. black | 11/0 | 13/0 | 14/0 | 8/1 |
| Median age, y (range) | 70 (53-81) | 57 (42-79) | 57.5 (36-80) | 58 (35-78) |
| Median duration of CTCL, y (range) | 2.2 (0.1-7.4) | 2.2 (0.5-13.7) | 5.3 (0.4-46.9) | 2.8 (0.8-7.5) |
CTCL indicates cutaneous T-cell lymphoma; MF/SS, mycosis fungoides/Śezary syndrome.